Operating Segments (Tables)

3 Months Ended

Mar. 31, 2017

Operating Segments [Abstract]

Summary of operating segments

	Three Months Ended  March 31,
	2017			2016
Revenues
Vaccines/BioDefense	$	1,330,884		$	2,630,986
BioTherapeutics		-			-
Total	$	1,330,884		$	2,630,986
Income/(Loss) from Operations
Vaccines/BioDefense	$	136,600		$	317,991
BioTherapeutics		(1,027,555	)		(1,245,585	)
Corporate		(847,235	)		(978,111	)
Total	$	(1,738,190	)	$	(1,905,705	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	9,769		$	10,019
BioTherapeutics		9,567			10,433
Corporate		1,714			2,155
Total	$	21,050		$	22,607
Interest Income (Expense), Net
Corporate	$	4,753		$	(3,885	)
Share-Based Compensation
Vaccines/BioDefense	$	17,998		$	28,006
BioTherapeutics		49,770			34,832
Corporate		78,859			73,573
Total	$	146,627		$	136,411

	As of  March 31, 2017		As of December 31, 2016
Identifiable Assets
Vaccines/BioDefense	$	1,073,536	$	1,297,986
BioTherapeutics		43,320		49,422
Corporate		7,292,354		8,919,698
Total	$	8,409,210	$	10,267,105